株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ワクチン受託製造市場の予測:主要国・技術・企業の分析

Global Vaccine Contract Manufacturing Market Report 2017-2027: Leading Countries, Technologies and Companies

発行 Visiongain Ltd 商品コード 347364
出版日 ページ情報 英文 154 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=154.30円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
ワクチン受託製造市場の予測:主要国・技術・企業の分析 Global Vaccine Contract Manufacturing Market Report 2017-2027: Leading Countries, Technologies and Companies
出版日: 2017年02月23日 ページ情報: 英文 154 Pages
概要

ワクチン受託製造市場は、2016年から2021年にかけて8.9%、2021年から2027年にかけて9.2%の複合年間成長率 (CAGR) で拡大する見込みです。治療ワクチン需要の拡大および人口の高齢化といった要因がワクチン受託製造事業を推進する見通しで、2027年には総収益が21億1700万米ドル規模に達すると予測されています。

当レポートは、世界のワクチン受託製造の市場を調査し、ワクチンの発展の経緯、仕組み、種類と概要、現在の製造技術、ワクチン製造の市場規模の推移と予測、ワクチン受託製造の市場規模の推移と予測、主要国における受託製造の市場規模の推移と予測、主要ワクチン受託製造機関のプロファイルおよび取り組みなどをまとめています。

第1章 レポート概要

第2章 ワクチンについて

  • ワクチンの歴史
  • ワクチンの仕組み
    • 人工免疫
  • ワクチンの各種タイプ
    • 弱毒性生ワクチン (LAV)
    • 組換え生ワクチン
    • 不活化ワクチン
    • トキソイドワクチン
    • サブユニットワクチン
    • 結合型ワクチン
    • 組換えサブユニットワクチン
    • DNAワクチン
    • 組換えベクターワクチン
    • 治療ワクチン
  • ワクチンで予防できる疾患
  • ワクチン市場の成長
  • 技術・法規制面の改善

第3章 現在のワクチン製造技術

  • サマリー:ワクチン技術の動向
  • ワクチン製造の新しい担体
    • 細胞培養ベースの製造技術へのシフト
    • 細胞培養ベースの製造のメリット
    • 哺乳類細胞株
    • 鳥類細胞株
    • 植物ワクチン
    • 昆虫類の卵ベースの製造システム
  • 次世代発現システム&ベクター:生産歩留の拡大
    • AdVac Technology:Crucell
    • AdCEV Vectors:AfriVax
    • Pfenex Expression Technology:Pfenex
  • 機器の動向
    • 使い捨て単回利用機器へのシフト
    • バイオリアクターとワクチンの製造
  • 充填済シリンジとワクチン
    • 充填済シリンジ市場の成長
    • 充填済ワクチン製品
    • 充填済ワクチン:成長推進因子・阻害因子
    • 製品の安定性・品質保証プログラム
  • 凍結乾燥とワクチン製造
  • 細胞培養基による製造歩留の改善

第4章 世界のワクチン製造市場の予測

  • 世界のワクチン製造市場の予測:概要
  • 世界のワクチン市場の予測
  • 世界のワクチン市場:区分別
  • ワクチン市場の成長とワクチン製造の高効率化
  • 小児ワクチン市場の概要
  • 成人用予防ワクチン市場の概要
  • インフルエンザワクチン市場の概要
  • 治療ワクチン市場の概要

第5章 世界のワクチン受託製造の予測

  • 医薬品・バイオテクノロジー産業におけるアウトソーシング
    • アウトソースの理由
    • アウトソーシングのメリット
    • ワクチン製造のアウトソーシングにおける課題
    • ワクチン製造を企業がアウトソースする理由
    • 戦略的アウトソーシング vs 戦術的アウトソーシング
  • 医薬品受託製造機関 (CMO)
    • CMOが提供する製造サービス
    • よくアウトソースされるワクチン製造活動
  • 医薬品受託製造市場:総収益の予測
  • ワクチン受託製造市場の予測
    • 市場規模実績
    • 市場予測

第6章 主要国におけるワクチン受託製造の予測

  • 主要国におけるワクチン受託製造
  • 主要国におけるワクチン受託製造の推移
  • 主要国におけるワクチン受託製造の予測
    • 米国
    • EU5カ国
      • ドイツ
      • イタリア
      • 英国
      • フランス
      • スペイン
    • 日本
    • 中国
    • インド
    • ロシア
    • ブラジル

第7章 主要ワクチン受託製造企業の予測

  • 主なワクチン受託製造機関
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika GmbH
  • Lonza
  • Meridian Life Science
  • Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • SynCo Bio Partners

第8章 ワクチン製造市場:世界的動向の予測

  • ワクチン受託製造産業の動向
  • SWOT分析

第9章 総論

  • 概要
  • 法規制・品質基準が参入の高い障壁に
  • 新興市場:高い成長の見通し

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0172

The global vaccine contract manufacturing market is expected to grow at a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from 2021-2027. The market is expected to grow at a CAGR of 9.1% from 2016 to 2027. The market is estimated at $816m in 2016, and $2117m in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 154-page report you will receive 74 charts - all unavailable elsewhere.

The 155-page report provides clear detailed insight into the global vaccine contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Revenue and growth forecasts to 2027 for the global vaccine market and market shares of the submarkets: paediatric vaccines, adult vaccines, influenza vaccines and therapeutic vaccines
  • Revenue and growth forecasts to 2027 for the global vaccine contract manufacturing market
  • Revenue and growth forecasts to 2027 for the leading national markets:
    • United States
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Japan
    • Brazil
    • Russia
    • China
    • India
    • Rest of the World
  • Revenue and growth forecasts to 2027 for the leading players in the vaccine contract manufacturing market:
    • Baxter BioPharma Solutions
    • Boehringer Ingelheim
    • Catalent
    • Charles River Laboratories
    • IDT Biologika
    • Lonza
    • Meridian Life Science
    • Sigma Aldrich Fine Chemicals
    • Merck
    • Synco Bio Partners
  • Analysis of what stimulates and restrains the global vaccine contract manufacturing market

Visiongain's study is intended for anyone requiring commercial analyses for the global vaccine contract manufacturing market. You find data, trends and predictions.

Buy our report today Global Vaccine Contract Manufacturing Market Report 2017-2027: Leading Countries, Technologies and Companies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. World Vaccine Contract Manufacturing Market Highlights
  • 1.2. Why You Should Read This Report?
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Vaccines

  • 2.1. The History of Vaccines
  • 2.2. How Do Vaccines Work?
  • 2.2.1. Artificial Immunity
  • 2.3. Types of Vaccine
    • 2.3.1. Live, Attenuated Vaccines (LAVs)
    • 2.3.2. Recombinant Live Vaccines
    • 2.3.3. Inactivated Vaccines
    • 2.3.4. Toxoid Vaccines
    • 2.3.5. Subunit Vaccines
    • 2.3.6. Conjugate Vaccines
    • 2.3.7. Recombinant Subunit Vaccines
    • 2.3.8. DNA Vaccines
    • 2.3.9. Recombinant Vector Vaccines
    • 2.3.10. Therapeutic Vaccines
  • 2.4. Diseases Preventable with Vaccines
  • 2.5. The Rise of the Vaccines Market
  • 2.6. Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 2017

  • 3.1. Summary of Vaccine Technology Trends
  • 3.2. New Substrates for Vaccine Production
    • 3.2.1. Shift towards Cell-Based Manufacturing Technology
    • 3.2.2. Benefits of Cell-Based Techniques
    • 3.2.3. Mammalian Cell Lines
      • 3.2.3.1. MCDK (Madin Darby Canine Kidney Cells)
      • 3.2.3.2. Vero Cells
      • 3.2.3.3. PerC6 Cells
    • 3.2.4. Avian-Derived Cell Lines
      • 3.2.4.1. EB66 Stem Cell Technology: Vivalis
    • 3.2.5. Plant-Based Vaccines
      • 3.2.5.1. Medicago's Proficia VLP Vaccine Technology
    • 3.2.6. Insect Egg-Based Production Systems
      • 3.2.6.1. Novavax
      • 3.2.6.2. Protein Sciences Corporation (PSC)
  • 3.3. Next-Generation Expression Systems and Vectors: Increasing Production Yield
    • 3.3.1. AdVac Technology: Crucell
    • 3.3.2. AdCEV Vectors: AfriVax
    • 3.3.3. Pfenex Expression Technology: Pfenex
  • 3.4. Equipment Trends
    • 3.4.1. The Shift Towards Disposable Single-use Equipment
    • 3.4.2. Bioreactors and Vaccine Production
      • 3.4.2.1. Single-Use Bioreactors
      • 3.4.2.2. Main Applications of Disposable Bioreactors
      • 3.4.2.3. Current Single-Use Bioreactor Systems on the Market
  • 3.5. Prefilled Syringes and Vaccines
    • 3.5.1. Growing Market for Pre-Filled Syringes
    • 3.5.2. Pre-Filled Vaccine Products
    • 3.5.3. Drivers and Restraints for Pre-Filled Syringes
    • 3.5.4. Product Stability and Quality Assurance Programme
      • 3.5.4.1. Paediatric H1N1 Vaccine
      • 3.5.4.2. Reported Challenges Flu Vaccines
      • 3.5.4.3. Novartis' Agriflu and Fluad Ban is Lifted
      • 3.5.4.4. Baxter Flu Vaccine and Side Effects
      • 3.5.4.5. Reported Shelf Life with H1N1 Vaccine
  • 3.6. Lyophilisation and Vaccine Manufacturing
    • 3.6.1. Lyophilisation of Vaccines Will Increase
  • 3.7. Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2017-2027

  • 4.1. Overview of the Global Vaccine Manufacturing Market 2017-2027
  • 4.2. World Vaccine Market Forecast 2017-2027
  • 4.3. The Global Vaccine Market by Submarket, 2016 and 2017
  • 4.4. Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
  • 4.5. Paediatric Vaccines Market Overview
  • 4.6. Adult Prophylactic Vaccines Market Overview
  • 4.7. Influenza Vaccines Market Overview
  • 4.8. Therapeutic Vaccines Market Overview

5. The Global Vaccine Contract Manufacturing 2017-2027

  • 5.1. Outsourcing in the Pharmaceutical and Biotechnology Industry
    • 5.1.1. Reasons to Outsource
    • 5.1.2. Benefits of Outsourcing
    • 5.1.3. The Challenges in Outsourcing Vaccine Manufacturing
    • 5.1.4. Why Should Companies Outsource Vaccine Manufacturing?
    • 5.1.5. Strategic Outsourcing vs. Tactical Outsourcing
    • 5.1.6. Virtual Companies
  • 5.2. Contract Manufacturing Organisations (CMOs)
    • 5.2.1. Manufacturing Services Offered by CMOs
    • 5.2.2. Vaccine Manufacturing Activities Typically Outsourced
  • 5.3. The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2016-2027
  • 5.4. Contract Manufacturing Market for Vaccines 2016-2027
    • 5.4.1. Market Size for Contract Manufacturing of Vaccines 2016
    • 5.4.2. Vaccine Contract Manufacturing Market Forecast 2016-2027

6. The Leading National Markets for Vaccine Contract Manufacturing, 2017-2027

  • 6.1. The Leading National Markets for Vaccine Contract Manufacturing
  • 6.2. The Leading National Markets for Vaccine Contract Manufacturing, 2016-2017
  • 6.3. The Leading National Markets for Vaccine Contract Manufacturing, 2016-2027
    • 6.3.1. The US Vaccine Contract Manufacturing Market Forecast, 2016-2027
    • 6.3.2. The EU5 Vaccine Contract Manufacturing Market, 2016 and 2017
      • 6.3.2.1. The EU5 Vaccine Contract Manufacturing Market, 2016-2027
      • 6.3.2.2. The German Vaccine Contract Manufacturing Market, 2016-2027
      • 6.3.2.3. The Italian Vaccine Contract Manufacturing Market, 2016-2027
      • 6.3.2.4. The UK Vaccine Contract Manufacturing Market, 2016-2027
      • 6.3.2.5. The French Vaccine Contract Manufacturing Market, 2016-2027
      • 6.3.2.6. The Spanish Vaccine Contract Manufacturing Market, 2016-2027
    • 6.3.3. The Japanese Vaccine Contract Manufacturing Market, 2016-2027
    • 6.3.4. The Chinese Vaccine Contract Manufacturing Market, 2016-2027
    • 6.3.5. The Indian Vaccine Contract Manufacturing Market, 2016-2027
    • 6.3.6. The Russian Vaccine Contract Manufacturing Market, 2016-2027
    • 6.3.7. The Brazilian Vaccine Contract Manufacturing Market, 2016-2027

7. Leading Vaccine Contract Manufacturing Companies, 2017-2027

  • 7.1. Leading Vaccine Contract Manufacturing Organisations
  • 7.2. Baxter BioPharma Solutions
  • 7.3. Boehringer Ingelheim
    • 7.3.1. Recent Financial Performance
    • 7.3.2. Ben Venue Laboratories
    • 7.3.3. Manufacturing Deals 2011-2017
  • 7.4. Catalent
    • 7.4.1. Recent Financial Performance
    • 7.4.2. Catalent: Financial Performance by Segment, 2011-2016
    • 7.4.3. Catalent Injectable Vaccines
    • 7.4.4. Catalent: Zydis Technology
    • 7.4.5. Regional Market Expansion Strategy
  • 7.5. Charles River Laboratories
    • 7.5.1. Recent Financial Performance, 2011-2014
    • 7.5.2. Financial Performance by Segment, 2010-2015
    • 7.5.3. Recent Financial Performance, 2015
    • 7.5.4. Vaccine Manufacturing Services
    • 7.5.5. Charles River Avian Vaccine Services
    • 7.5.6. Vaccine Manufacturing Expansion
    • 7.5.7. Outlook and Early Stage Restructuring
    • 7.5.8. Partnerships
      • 7.5.8.1. Partnership with AstraZeneca
      • 7.5.8.2. Partnership with Batavia
  • 7.6. IDT Biologika GmbH
  • 7.7. Lonza
    • 7.7.1. Recent Financial Performance
    • 7.7.2. Financial Performance in H1 2015
    • 7.7.3. Manufacturing Division Restructuring
  • 7.8. Meridian Life Science
    • 7.8.1. Recent Financial Performance, 2010-2016
    • 7.8.2. Recent Financial Performance by Segment, 2011-2016
  • 7.9. Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • 7.10. SynCo Bio Partners
    • 7.10.1. Recent Developments
      • 7.10.1.1. Expansion of Facilities
      • 7.10.1.2. FDA Approval of Partner Application

8. Vaccine Manufacturing Market: World Market Trends 2017-2027

  • 8.1. Vaccine Contract Manufacturing Industry Trends
  • 8.2. Strengths
    • 8.2.1. Many Companies Cannot Afford In-house Capabilities
    • 8.2.2. Outsourcing Improves Time to Market
    • 8.2.3. Manufacturers Get Access to Specialised Technologies
    • 8.2.4. Shift Towards Emerging Markets as Favourable Outsourcing Destinations
  • 8.3. Weaknesses
    • 8.3.1. Mass Vaccine Manufacturing Kept In-house
    • 8.3.2. A Highly-Fragmented Vaccine Contract Manufacturing Market
    • 8.3.3. An Unpredictable Supply and Demand Business Model
  • 8.4. Opportunities
    • 8.4.1. Many Vaccines in the Product Pipeline
    • 8.4.2. Emerging Market's Growing Demand for Vaccines
      • 8.4.2.1. Dynamic Change: Emerging Markets are Major Vaccine Developers
    • 8.4.3. Changing World Demographics
  • 8.5. Threats
    • 8.5.1. Post Recession: Biotech Suffer from Severe Cuts in Capital Funding
    • 8.5.2. The Public are Slow to Accept Novel Technologies
    • 8.5.3. Perception of Risk by the Original Vaccine Manufacturers

9. Conclusion

  • 9.1. Overview
  • 9.2. Regulatory and Quality Standards Create High Barriers of Entry
  • 9.3. Emerging Markets Will Show Stronger Growth

Appendix A

  • About Visiongain

Appendix B

  • Visiongain report evaluation form

List of Figures

  • Figure 3.1: Influenza Vaccine Production Using a Cell-Based Manufacturing Method
  • Figure 3.2: Medicago's Product Pipeline
  • Figure 3.3: Novavax' Insect Egg-Based Vaccine Production Process
  • Figure 3.4: Pre-filled Syringes Market: Drivers and Restraints, 2017-2027
  • Figure 4.1: The Global Vaccine Market Forecast: Revenue ($bn) and AGR (%) 2016-2027
  • Figure 4.2: The Global Vaccine Market: Market Share by Submarket (%), 2017
  • Figure 5.1: Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry
  • Figure 5.2: The Global Pharmaceutical Contract Manufacturing Forecast: Revenue ($bn), 2016, 2021 and 2027
  • Figure 5.3: The Global Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.1: The Leading National Vaccine Contract Manufacturing Markets: Market Share (%) by Region, 2016
  • Figure 6.2: The US Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%),2016-2027
  • Figure 6.3: The EU5 Vaccine Contract Manufacturing Markets: Market Share (%) by Country, 2017
  • Figure 6.4: The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.5: The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.6: The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.7: The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.8: The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.9: The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.10: The Japanese Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Figure 6.11: The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2016-2027
  • Figure 6.12: The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2016-2027
  • Figure 6.13: The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.14: The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.1: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2015
  • Figure 7.2: Catalent: Revenue ($m) and AGR (%), 2010-2015
  • Figure 7.3: Catalent: Revenue ($m) by Segment, 2011-2016
  • Figure 7.4: Catalent: Marker Shares (%) by Segment, 2016
  • Figure 7.5: Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2015
  • Figure 7.6: Charles River Laboratories: Quarterly Revenue ($m) by Segment, 2014-2015
  • Figure 7.7: Lonza Custom Manufacturing: Revenue ($m )and AGR (%), 2010-2015
  • Figure 7.8: Meridian Bioscience: Revenue ($m), and AGR (%), 2010-2016
  • Figure 7.9: Meridian Bioscience: Revenue ($m) by Segment, 2011-2016
  • Figure 7.10: Meridian Bioscience: Market Share (%) by Segment,2016
  • Figure 8.1: Drivers and Restraints for the Vaccine Contract Manufacturing Sector, 2017-2027

List of Tables

  • Table 2.1: Timeline of Key Events in Vaccine Development, c.1000 AD - Present
  • Table 3.1: Vaccine Development Pipeline Using Crucell's AdVac Technology
  • Table 3.2: Benefits and Drawbacks of Using Disposable Technology for Vaccine Production
  • Table 3.3: Companies Providing Disposable Biomanufacturing Platforms/Systems
  • Table 3.4: Some Leading Pre-Filled Syringe Vaccine Products
  • Table 3.5: Prominent Lyophilised Vaccines
  • Table 3.6: Examples of Serum-Free Media for Vaccine Manufacturing
  • Table 4.1: The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.2: The Global Vaccine Market: Revenue ($bn) and Market Share by Submarket (%), 2016-2017
  • Table 5.1: The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.1: The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m) and Market Share (%), 2016-2017
  • Table 6.2: The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.3: The Leading National Vaccine Contract Manufacturing Markets Forecast: Market Shares (%), 2016 and 2027
  • Table 6.4: The US Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.5: The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m) and Market Share (%) by Country, 2016-2017
  • Table 6.6: The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.7: The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.8: The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.9: The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.10: The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.11: The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.12: The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.13: The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.14: The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.15: The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.16: The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2015
  • Table 7.2: Catalent: Revenue($m) and AGR (%), 2010-2016
  • Table 7.3: Catalent by Segment: Revenue($m), AGR (%), and Intersegment Revenue Eliminations, 2011-2016
  • Table 7.4: Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2015
  • Table 7.5: Charles River Laboratories: Newly Revised Reportable Segments
  • Table 7.6: Charles River Laboratories: Revenue ($bn) by Segment, 2010-2012
  • Table 7.7: Charles River Laboratories: Revenue ($bn) by Segment, 2013-2015
  • Table 7.8: Charles River Laboratories: Quarterly Revenue ($m) by Segment, 2015
  • Table 7.9: Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities
  • Table 7.10: Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2015
  • Table 7.11: Meridian Bioscience: Revenue ($m), AGR (%), 2010-2016
  • Table 7.12: Meridian Bioscience: Revenue ($m) and AGR (%) by Segment, 2011-2017
  • Table 7.13: SynCo Bio Partners Capabilities
  • Table 8.1: SWOT Analysis of the Vaccine Contract Manufacturing Market, 2017-2027

Companies Listed

  • Aeras Global
  • AfriVax
  • AmProtein
  • Antigenics Inc.
  • Artelis
  • AstraZeneca
  • ATM Life Sciences
  • AVEO Pharmaceuticals
  • Baxter BioPharma Solutions
  • Bayer
  • Beijing Tiantan Biological Productions
  • Berna Biotech
  • Bharat Biotech International Limited
  • Binnopharm
  • BioKangtai
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Biovest
  • Boehringer Ingelheim Biopharmaceuticals (China)
  • Cadila Pharmaceuticals
  • Catalent
  • Cellexus Limited
  • Center for Disease Control (CDC)
  • China Food and Drug Administration (CFDA)
  • Crucell
  • CSL Biotherapies
  • Daiichi Sankyo
  • Dalian Hissen Bio-Pharm
  • Defense Advanced Research Projects Agency (DARPA)
  • Food and Drug Administration (FDA)
  • FiberCell
  • GE Healthcare
  • GlaxoSmithKline
  • Hikma
  • Hualan Biological Bacterin
  • Hyclone
  • Institut Pasteur
  • Intercell Corporation
  • Invitrogen
  • Irvine Scientific
  • Kuhner
  • LG Life Sciences
  • Lonza
  • Medicago
  • Meissner Filtration
  • Merck
  • Merck Serono
  • Micron Technologies
  • Millipore
  • Mitsubishi Tanabe Pharma (MTPC)
  • MorphoSys
  • MP Biomedicals
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Novartis
  • Novavax
  • Organon Teknika Corporation
  • Pall Life Sciences
  • Paragon Bioservices
  • Patheon
  • PBS Biotech
  • Pfenex
  • Pfizer
  • Philip Morris Investments
  • Pierre-Guerin Biolafitte
  • Protein Sciences Corporation
  • Refine Technology
  • Sanofi
  • Sartorius Stedim
  • Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd.
  • Sigma Aldrich
  • Thermo Fisher
  • U.S Department of Homeland Security
  • U.S. Department of Health and Human Services Office
  • Vector Solutions
  • Vivalis
  • Wave Biotech
  • World Health Organisation (WHO)
  • Wyeth Pharmaceuticals
  • Xcellerex
  • Xencor
Back to Top